Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed (confirmed by tissue testing) with a WHO Grade II or III meningioma (a type of brain tumour) that has either remained after surgery, grown again, or come back, after having both surgery and radiation therapy. Spread of the meningioma to other areas is also allowed.
• People whose tumour can be measured on an MRI scan, meaning it shows up clearly and measures at least 10mm in two directions.
• People who have already had the maximum amount of surgery and radiation therapy that is safely possible for their tumour.
• People who have been on a stable or reducing dose of steroid medication for at least five days before signing the consent form.
• People who are at least 12 years of age.
• People who are well enough to carry out some daily activities, as rated by standard medical scoring tools (ECOG 0–2 or KPS 60 or above — confirm with trial site if unsure what this means for a specific situation).
• People who are expected to survive for at least three months.
• People whose blood test results show that their bone marrow, liver, and kidneys are working adequately, based on specific laboratory values (the trial site can confirm the exact numbers required).
• People who are willing to provide a blood sample to help measure how the study drug moves through the body.
• People who have had an MRI scan (or CT scan if MRI is not possible) within 14 days before starting the study drug, taken while on a stable or decreasing steroid dose for at least five days.
• People who have recovered from most side effects of previous treatments down to a mild level or back to their usual baseline before treatment.
• People who have had previous treatments such as chemotherapy, radiation, or radiosurgery, as long as enough time has passed since each treatment (for example, at least 12 weeks since radiation therapy, at least 4 weeks since most chemotherapy, or at least 28 days since surgery — the trial site can confirm the exact timing requirements).
• Women who could potentially become pregnant, and male participants, who agree to use adequate contraception from 30 days before the first dose through to 90 days after completing the study.
• Women who are not currently pregnant, confirmed by a negative blood pregnancy test taken within seven days before starting the study drug.
• Women who are not breastfeeding.
• People who are willing and able to attend all scheduled visits, follow the treatment plan, and complete all study requirements, confirmed by signing a written consent form.

Who may not be able to join:

• People who have received chemotherapy, targeted therapy, or another experimental treatment within 14 days (or within 5 half-lives of the drug, whichever is shorter) before starting the study drug.
• People who finished a combined chemotherapy and radiation treatment within the past 84 days, unless there is confirmed new tumour growth outside the radiation area or tissue-proven recurrence.
• People who had surgery within seven days before signing the consent form.
• People who received a specific type of internal radiation therapy (brachytherapy) within the past six months.
• People who are currently taking part in, or planning to join, another clinical trial using an experimental drug or device.
• People whose tumour is located mainly in the brainstem or spinal cord.
• People who have not yet recovered from side effects caused by previous chemotherapy, immunotherapy, or radiation therapy.
• People who have previously been treated with the study drug perillyl alcohol.
• People who have had an allergic reaction to perillyl alcohol in the past.
• People with uncontrolled ongoing health conditions, such as an active serious infection, uncontrolled heart failure, unstable chest pain, irregular heart rhythm, or mental health or personal circumstances that would make it difficult to follow the study requirements.
• People who are currently pregnant or breastfeeding.
• People who have been diagnosed with or treated for another cancer (other than this meningioma) within the past five years — with the exception of certain common skin cancers (basal cell or squamous cell carcinoma of the skin).
• People whose tumour has spread to the lining surrounding the brain and spinal cord (called leptomeningeal involvement).

Important: Always verify eligibility with the trial site directly before applying.